Genetic design of an optimized packaging cell line for gene vectors transducing human B cells

Gene Therapy

Volumn 13, Issue 10, 2006, Pages 844-856

  Hettich, E ^a,b   Janz, A ^a,b   Zeidler, R ^b   Pich, D ^a   Hellebrand, E ^a   Weissflog, B ^a,c   Moosmann, A ^a,c   Hammerschmidt, W ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Vaecgene Biotech Inc   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Epstein Barr virus; Gene vector; Herpesvirus; Virus free packaging cell line

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; B LYMPHOCYTE; CELL BASED GENE THERAPY; CELL LINE; CONTROLLED STUDY; DNA MODIFICATION; DNA PACKAGING; EPSTEIN BARR VIRUS; GENE MUTATION; GENE VECTOR; GENETIC TRANSDUCTION; GENOME ANALYSIS; HELPER VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; PLASMID; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

B-LYMPHOCYTES; CELL LINE; DNA, VIRAL; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELPER VIRUSES; HERPESVIRUS 4, HUMAN; HUMANS; POLYMERASE CHAIN REACTION; RECOMBINATION, GENETIC; TRANSDUCTION, GENETIC; TRANSFECTION; VIRUS ASSEMBLY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; PROKARYOTA;

EID: 33646359946     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302714     Document Type: Article

References (61)

1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
2. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
3. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM et al. (eds), Fields' Virology. Lippincott, Williams & Wilkins: Philadelphia, 2001, pp 2511-2573.
4. Janz A, Oezel M, Kurzeder C, Mautner J, Pich D, Kost M et al. Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol 2000; 74: 10142-10152.
5. Wang J, Sugden B. Origins of bidirectional replication of Epstein-Barr virus: Models for understanding mammalian origins of DNA synthesis. J Cell Biochem 2005; 94: 247-256.
6. Wang J, Vos JM. Infectious Epstein-Barr virus vectors for episomal gene therapy. Methods Enzymol 2002; 346: 649-660.
7. White RE, Wade-Martins R, James MR. Infectious delivery of 120-kilobase genomic DNA by an Epstein-Barr virus amplicon vector. Mol Ther 2002; 5: 427-435.
8. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Ther 2001; 3: 454-463.
9. Wade-Martins R, Saeki Y, Chiocca EA. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 2003; 7: 604-612.
10. Adler H, Messerle M, Koszinowski UH. Cloning of herpesviral genomes as bacterial artificial chromosomes. Rev Med Virol 2003; 13: 111-121.
11. Neuhierl B, Delecluse HJ. Molecular genetics of DNA viruses: Recombinant virus technology. Methods Mol Biol 2005; 292: 353-370.
12. Borst EM, Posfai G, Pogoda F, Messerle M. Mutagenesis of herpesvirus BACs by allele replacement. Methods Mol Biol 2004; 256: 269-279.
13. Kolisnychenko V, Plunkett III G, Herring CD, Feher T, Posfai J, Blattner FR et al. Engineering a reduced Escherichia coli genome. Genome Res 2002; 12: 640-647.
14. Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med 2003; 76: 51-60.
15. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 2001; 19: 1067-1070.
16. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998; 72: 7137-7143.
17. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
18. Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus. In: Knipe DM et al. (eds), Fields' Virology. Lippincott, Williams & Wilkins: Philadelphia, 2001, pp 2803-2833.
19. Delecluse HJ, Pich D, Hilsendegen T, Baum C, Hammerschmidt W. A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci USA 1999; 96: 5188-5193.
20. Wendtner CM, Kurzeder C, Theiss HD, Kofler DM, Baumert J, Delecluse HJ et al. High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors. Exp Hematol 2003; 31: 99-108.
21. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 1998; 95: 8245-8250.
22. Neuhierl B, Feederle R, Hammerschmidt W, Delecluse HJ. Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci USA 2002; 99: 15036-15041.
23. Wilkinson DE, Weller SK. Recruitment of cellular recombination and repair proteins to sites of herpes simplex virus type 1 DNA replication is dependent on the composition of viral proteins within prereplicative sites and correlates with the induction of the DNA damage response. J Virol 2004; 78: 4783-4796.
24. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000; 19: 3080-3089.
25. Zimmermann J, Hammerschmidt W. Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA. J Virol 1995; 69: 3147-3155.
26. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (London) 1989; 340: 393-397.
27. Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989; 86: 9558-9562.
28. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res 2003; 63: 2982-2989.
29. O'Connor M, Peifer M, Bender W. Construction of large DNA segments in Escherichia coli. Science 1989; 244: 1307-1312.
30. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998; 17: 1700-1709.
31. Kempkes B, Pich D, Zeidler R, Hammerschmidt W. Immortalization of human primary B lymphocytes in vitro with DNA. Proc Nat Acad Sci USA 1995; 92: 5875-5879.
32. Griffin BE, Björck E, Bjursell G, Lindahl T. Sequence complexity of circular Epstein-Barr virus DNA in transformed cells. J Virol 1981; 40: 11-19.
33. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993; 90: 9150-9154.
34. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 1993; 67: 2014-2025.
35. Kempkes B, Pich D, Zeidler R, Sugden B, Hammerschmidt W. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol 1995; 69: 231-238.
36. Pfuller R, Hammerschmidt W. Plasmid-like replicative intermediates of the Epstein-Barr virus lytic origin of DNA replication. J Virol 1996; 70: 3423-3431.
37. Hellebrand E, Mautner J, Reisbach G, Nimmerjahn F, Hallek M, Mocikat R et al. Epstein-Barr virus vector-mediated gene transfer into human B cells: Potential for antitumor vaccination. Gene Therapy 2005 (Epub ahead of print).
38. Feederle R, Shannon-Lowe C, Baldwin G, Delecluse HJ. Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative Epstein-Barr virus. J Virol 2005; 79: 7641-7647.
39. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J et al. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100: 2757-2765.
40. Pansegrau W, Lanka E, Barth PT, Figurski DH, Guiney DG, Haas D et al. Complete nucleotide sequence of Birmingham IncP alpha plasmids. Compilation and comparative analysis. J Mol Biol 1994; 239: 623-663.
41. Mindich L, Cohen J, Weisburd M. Isolation of nonsense suppressor mutants in Pseudomonas. J Bacteriol 1976; 126: 177-182.
42. Hammerschmidt W, Sugden B. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol Med 2004; 10: 331-336.
43. Damania B. Oncogenic gamma-herpesviruses: Comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2004; 2: 656-668.
44. Schepers A, Pich D, Hammerschmidt W. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J 1993; 12: 3921-3929.
45. Altmann M, Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 2005; 3: E404.
46. Dirmeier U, Hoffmann R, Kilger E, Schultheiss U, Briseno C, Gires O et al. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005; 24: 1711-1717.
47. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996; 15: 3117-3126.
48. Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 2003; 100: 14269-14274.
49. Kang MS, Lu H, Yasui T, Sharpe A, Warren H, Cahir-McFarland E et al. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci USA 2005; 102: 820-825.
50. Kang MS, Hung SC, Kieff E. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci USA 2001; 98: 15233-15238.
51. Hung SC, Kang MS, Kieff E. Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci USA 2001; 98: 1865-1870.
52. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
53. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995; 182: 1265-1273.
54. Pulvertaft JV. Cytology of Burkitt's tumour (African Lymphoma). Lancet 1964; 39: 238-240.
55. Miller G, Shope T, Lisco H, Stitt D, Lipman M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci USA 1972; 69: 383-387.
56. Hammerschmidt W, Sugden B. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 1988; 55: 427-433.
57. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81: 495-504.
58. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (London) 1984; 310: 207-211.
59. Posfai G, Koob MD, Kirkpatrick HA, Blattner FR. Versatile insertion plasmids for targeted genome manipulations in bacteria: Isolation, deletion, and rescue of the pathogenicity island LEE of the Escherichia coli O157:H7 genome. J Bacteriol 1997; 179: 4426-4428.
60. Ihara M, Oda Y, Yayamoto K. Convenient construction of strains useful for transducing recA mutations with bacteriophage P1. FEMS Microbiol Lett 1985; 30: 33-35.
61. Gruffat H, Batisse J, Pich D, Neuhierl B, Manet E, Hammerschmidt W et al. Epstein-Barr virus mRNA export factor EB2 is essential for production of infectious virus. J Virol 2002; 76: 9635-9644.